Last reviewed · How we verify
IMP Pioglitozone
Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose in type 2 diabetes.
Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose in type 2 diabetes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | IMP Pioglitozone |
|---|---|
| Sponsor | University of Nottingham |
| Drug class | Thiazolidinedione (PPAR-γ agonist) |
| Target | PPAR-γ (Peroxisome proliferator-activated receptor gamma) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
As a thiazolidinedione, pioglitazone binds to PPAR-γ in adipose tissue and muscle, enhancing insulin-mediated glucose uptake and reducing hepatic glucose production. This mechanism addresses insulin resistance, the underlying pathophysiology of type 2 diabetes, rather than stimulating insulin secretion directly.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Weight gain
- Fluid retention / edema
- Hypoglycemia (when combined with other agents)
- Headache
- Myalgia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IMP Pioglitozone CI brief — competitive landscape report
- IMP Pioglitozone updates RSS · CI watch RSS
- University of Nottingham portfolio CI